New company will focus on developing bispecific antibodies for rare bleeding disorders
News
RDIF confirms Sputnik V COVID vaccine’s efficacy
The Russian Direct Investment Fund has released a new analysis of data obtained 21 days after administering the first dose of the vaccine, showing efficacy of 91.4%
Pandemic has made little positive impact on public’s view of pharma
A new report launched by Takeda has found that just 17% of UK adults surveyed felt their perception of pharma had improved based on the industry’s response to COVID-19
Green light for UK trial of nasal coronavirus vaccine
The trial is expected to begin next month, with first data anticipated in the second quarter of 2021
New variant of coronavirus identified in the UK
PHE says it is investigating more than a thousand cases of the new strain
NICE u-turn on Novartis’ migraine drug Aimovig
New analyses submitted by Novartis has helped to secure a NICE recommendation for NHS funding
Novartis’ cholesterol med Leqvio wins EU approval
Drug approved to help reduce cholesterol levels
EU nod for AZ’ COPD maintenance therapy
The triple combination therapy Trixeo Aerosphere cut the rate of moderate or severe exacerbations compared with dual-combination therapies in clinical trials
Bumper December meeting sees CHMP recommend 15 new medicines
Ehertu, Inrebic and Retsevmo among positive recommendations
Albireo submits rare liver disease med odevixibat to FDA and EMA
If approved, drug will become first treatment for PFIC patients in the US and EU
CRUK researchers develop new early-stage rectal cancer treatment
New treatment could prevent debilitating side effects of standard major surgery
Alunbrig scores NICE backing for ALK-positive lung cancer
ALK inhibitor recommended in the first-line non-small cell lung cancer setting
Sanofi, GSK face COVID-19 vaccine trial delay
Potential availability of vaccine now delayed to the end of 2021
Crescendo Biologics expands Takeda collaboration
Follows previous agreements signed in November 2018 and July 2019
FDA set to review GSK’s Nucala for nasal polyps
Submission is based on data from the pivotal SYNAPSE study
